Kailera Therapeutics, Inc. Common Stock (KLRA)vsRegeneron Pharmaceuticals Inc (REGN)
KLRA
Kailera Therapeutics, Inc. Common Stock
$10.39
-5.80%
HEALTHCARE · Cap: $1.55B
REGN
Regeneron Pharmaceuticals Inc
$735.20
+0.05%
HEALTHCARE · Cap: $82.55B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 27.9% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 66/100 (B-).
KLRA
Avoid31
out of 100
Grade: F
REGN
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KLRA.
Margin of Safety
+46.3%
Fair Value
$1397.14
Current Price
$735.20
$661.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 33.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Earnings declined 4.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : KLRA
The strongest argument for KLRA centers on Price/Book, Debt/Equity.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Debt/Equity, Altman Z-Score. Profitability is solid with margins at 27.9% and operating margin at 33.1%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
KLRA profiles as a value stock while REGN is a growth play — different risk/reward profiles.
REGN is growing revenue faster at 16.7% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (66/100 vs 31/100), backed by strong 27.9% margins and 16.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kailera Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kailera Therapeutics, Inc. is a cutting-edge biotechnology company dedicated to developing innovative gene therapies for rare genetic diseases, addressing critical unmet medical needs. Utilizing its proprietary platform, Kailera aims to enhance the precision and effectiveness of therapeutic interventions across various genetic disorders. Backed by a strong intellectual property portfolio and strategic collaborations with premier research institutions, the company is poised to emerge as a leader in the gene therapy sector. As it progresses with a promising pipeline of products, Kailera Therapeutics is committed to delivering long-term value for its investors while significantly improving patient outcomes.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?